Format

Send to

Choose Destination
Br J Haematol. 2020 Mar 9. doi: 10.1111/bjh.16558. [Epub ahead of print]

Distinct mutational pattern of myelodysplastic syndromes with and without 5q- treated with lenalidomide.

Author information

1
MDS Research Group, Josep Carreras Leukaemia Research Institute, Institut Català d'Oncologia-Hospital Germans Trias i Pujol, Universitat Autonoma de Barcelona, Badalona, Spain.
2
Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.
3
Assistance Publique - Hôpitaux de Paris, Service Hematologie Clinique, Hôpital Universitaire Henri Mondor, Creteil, France.
4
Assistance Publique-Hopitaux de Paris, Service d'Hematologie Biologique, Hopitaux Universitaires Paris Centre, Paris, France.
5
Unidad de Diagnóstico Molecular y Celular del Cáncer, IBSAL, IBMCC-Centro de Investigación del Cáncer (USAL-CSIC), Universidad de Salamanca, Salamanca, Spain.
6
Department of Medicine, Universidad de Salamanca, Salamanca, Spain.
7
Department of Hematology, Hospital Universitario de Salamanca, Salamanca, Spain.
8
Laboratorio de Citogenetica, Servicio de Hematología, Hospital Universitario fundación Jimenez Díaz, Madrid, Spain.
9
Hematology Service, Hospital Universitario y Politécnico La Fe, Valencia, Spain.
10
Centro de Investigacion Biomédica en Red de Cáncer (CIBERONC), Instituto Carlos III, Madrid, Spain.
11
Departamento de Ciencias Biomédicas, Facultad de Ciencias de la Salud, Universidad CEU Cardenal Herrera, Hematology Service, Hospital Universitario y Politécnico La Fe, Valencia, Spain.
12
Centro de Investigación Biomédica en Red de Cáncer, Genetics Unit, Hospital Universitario y Politécnico La Fe, Valencia, Spain.
13
Department of Genetics, School of Medicine, University of Navarra, IDISNA, Pamplona, Spain.
14
Hematology Service, ICO-Hospital Germans Trias i Pujol, Josep Carreras Leukaemia Research Institute, Universitat Autonoma de Barcelona, Badalona, Spain.
15
Scientific & Innovation Department, Nimgenetics, Madrid, Spain.

KEYWORDS:

Myelodysplastic syndromes; del(5q); lenalidomide; mutations; non-del(5q)

PMID:
32147816
DOI:
10.1111/bjh.16558

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center